Sutro Biopharma (NASDAQ:STRO) Earns Neutral Rating from HC Wainwright
HC Wainwright reaffirmed their neutral rating on shares of Sutro Biopharma (NASDAQ:STRO – Free Report) in a research note published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $2.00 price objective on the stock. Other equities analysts also recently issued research reports about the stock. Bank of America downgraded shares of Sutro Biopharma from […]
More Stories
Freight Train Derails in Connecticut, Sending Cars Carrying Liquid Propane Into River
By The Associated Press MANSFIELD, Conn.—A freight train derailed Thursday in Connecticut, sending cars carrying flammable liquid propane into the...
Trump Calls for New Nuclear Arms Control Treaty as New START Expires
By Ryan Morgan U.S. President Donald Trump called for a new nuclear arms control treaty on Feb. 5, as the...
Bitcoin Slips Below $70,000 as Crypto Sell-Off Continues
By Andrew Moran Winter has arrived in the cryptocurrency market, as bitcoin has fallen below $70,000 for the first time...
Trump Launches TrumpRx Website for Discount Pharmaceutical Drugs
By Travis Gillmore President Donald Trump addressed the nation on Thursday night to announce the launch of TrumpRx.com featuring medicine...
Netflix CEO Faces Criticism From Lawmakers on Warner Merger
By Kevin Stocklin While Congress may have little say in whether Netflix’s proposed merger with Warner Bros. goes through, senators...
Georgia’s Fulton County Sues for Return of 2020 Election Documents Seized by FBI
By Matthew Vadum Fulton County, Georgia, is suing the federal government for the return of 2020 election documents that the...